Advancing Precision Oncology Through Translational Science - Dr. Rhoda Alani
By: Gayatri Srinivas
Conference Manager, InnoPharm 2026
01/22/2026
Dr. Rhoda Alani to Deliver Keynote Session (In-Person) at InnoPharm-2026.
InnoPharm-2026 is pleased to welcome Dr. Rhoda Alani, Professor at Harvard Medical School and Brigham and Women’s Hospital, as a Keynote Speaker.
Dr. Alani is a leading authority in cancer biology, with a particular focus on melanoma and skin cancers. Her work bridges the gap between fundamental molecular research and clinical application, aiming to translate biological discoveries into effective, targeted therapies.
Her research has contributed to a deeper understanding of tumor progression, resistance mechanisms, and the role of genetic and environmental factors in cancer development. By integrating laboratory science with patient-focused research, Dr. Alani has played a key role in advancing precision oncology.
Why It Matters:
As cancer treatment moves toward personalized approaches, the ability to translate molecular insights into targeted therapies is more important than ever. Dr. Alani’s work exemplifies this transition, contributing to improved treatment strategies and better patient outcomes.
About Dr. Alani:
- Professor, Harvard Medical School
- Researcher at Brigham and Women’s Hospital
- Leader in melanoma and cancer biology
- Expert in translational and precision oncology